The Celgene and Sorrento-backed immunotherapy drug developer initially raised $207m when it floated on Nasdaq last week.
NantKwest, a US-based immune-oncology company backed by pharmaceutical companies Celgene and Sorrento, closed its initial public offering at $238.3m on Friday.
The company initially raised $207m last week when it issued almost 8.3 million shares on Nasdaq priced at $25 each. Its $2.6bn market cap was reportedly the largest ever in a biotechnology IPO.
NantKwest raised an additional $31m when underwriters BofA Merrill Lynch, Citigroup Global Markets, Jefferies, Piper Jaffray and MLV & Co took up the option…
